and defect transformation of the spiral arteries in spontaneous abortions. 7 Immunological factors, 8 chromosomal aberrations, 9 thrombophilia, 10 impaired placental circulation, 7, 11 adenomyosis 12 , and anomalies of the uterus 13 are suggested risk factors, although the condition is of unknown cause in the vast majority of couples. 1 Without proper evidence for an effect, treatments like acetylsalicylic acid (ASA), low-molecular-weight heparin, immunoglobulin, progesterone, and immunization have been used when no etiological factor has been detected. The hypotheses for treatment with ASA or low-molecular-weight heparin or a combination of those are based on impaired placental circulation; a prothrombotic female phenotype, 14 increased levels of procoagulant factors and decreased levels of naturally occurring anticoagulants during pregnancy, 15 circulating procoagulant micro-particles, 16 defective maternal hemostatic response leading to thrombosis of the uteroplacental vasculature, subsequent fetal loss, 17 and activation of platelet aggregation. 18 Microthrombi and thromboses of placental vessels are common findings, 19 which may support anticoagulation therapy. It has been argued that ASA prevents placental thromboses. 20 We conducted a systematic search in the Cochrane Library, PubMed and Embase for studies that reported on treatments with ASA for RPL. 21 In couples with at least 3 consecutive miscarriages, ASA is sparsely investigated in randomized clinical trials (RCT) and has mostly been included together with other drugs. 11, 22 Only 1 small RCT including 54 patients has compared 50 mg ASA with placebo, resulting in the same live birth rate of 81%. 23 The aim of this study was to evaluate if 75 mg ASA prevents fetal loss during the first trimester in couples with at least three previous confirmed consecutive miscarriages of unknown etiology.
| MATERIAL AND ME THODS
Between 2008 and 2016, a double-blind, placebo-controlled RCT was conducted at Södra Älvsborg Hospital, Borås, Sweden. RPL was defined as at least three consecutive miscarriages in the first trimester within the couple and of unknown etiology.
| Participants
Women, who had experienced three or more consecutive miscarriages in the first trimester (including gestational length of 12 weeks and 6 days) in the same relationship, were eligible. Further inclusion criteria were a negative workup, a body mass index < 35 kg/m 2 , age < 40 years at the start of the investigation, and no allergy against ASA. Women who had already taken part in the study, had ongoing conflicting medical treatment, or had an in vitro fertilization (IVF) pregnancy for which the reason for IVF was recurrent miscarriage, were excluded.
The couples were referred or referred themselves to the study hospital in Borås, mostly from local hospitals and outpatient clinics in the western region of Sweden but also from longer distances within the country. All referred couples had a primary interview by phone with the principal investigator (PI). The medical and obstetrical history and heredity factors were discussed, and inclusion/exclusion criteria were checked.
A subsequent consultation with the PI included general and gynecological examination, transvaginal ultrasound, hydrosonography for examination of the uterine cavity, and measurement of blood pres- were eligible for randomization after the workup was completed and found negative, and after written consent had been provided by both partners in the couple.
| Randomization
The randomization list and the code key were computer generated by Apoteket Produktion & Laboratorier (APL), Stockholm, Sweden, ensuring concealed allocation. The randomization was stratified for age (< 33/≥ 33 years), in blocks of 20 and in a 1 : 1 ratio for ASA : placebo.
The age of 33 years was based on mean age in a representative local hospital population for this condition. The reason for stratification for age was to ascertain similar age-related fertility in both groups. The parcels were labeled and numbered by APL and subsequently sent to the pharmacy at Södra Älvsborg Hospital. After a positive pregnancy test followed by the verification of pregnancy with detectable fetal heartbeat, a form was filled out and sent by fax to the pharmacy at Södra Älvsborg Hospital, where the form was completed with a code number in consecutive order. The parcel was collected by the patient at the pharmacy or sent to the local hospital for distribution to the patient.
Key Message
This randomized, double-blind, placebo-controlled, singlecenter study demonstrates that treatment with 75 mg acetylsalicylic acid does not prevent recurrent miscarriage in the first trimester.
| Interventions
The parcels and the study pills containing the ASA or placebo, produced by APL, were identical in appearance. The study pills were produced in two series to ensure drug efficacy overtime. The active treatment was 75 mg ASA and control women received placebo pills.
The treatment started directly after randomization. Check-ups were planned for gestational weeks 9, 13, 20, 30, and 36. The study drug was discontinued at the check-up in gestational week 36. Visits included ordinary obstetric surveillance, registration of adverse events including vaginal bleeding, fetal growth, and side effects of treatment. A final sum-up of the pregnancy including delivery and the condition of mother and child was made by the PI by phone 3 weeks after delivery. All patients attended the same control program.
| Compliance
The adherence to treatment was controlled at each check-up. At the final visit at 36 gestational weeks, the number of remaining pills was communicated to the PI or the local gynecologist. In addition, samples for analysis of platelet aggregation were collected before and during pregnancy.
| Outcomes
The primary outcome was live birth after at least 24 completed gestational weeks. Prespecified secondary outcomes were miscarriage before entering gestational week 24, antenatal vaginal bleeding, placenta previa, preterm delivery (before 37 gestational weeks), small-
for-gestational-age (defined as birthweight below −2 SD [<−22%]
according to the Swedish reference value for singletons, with adjustment for gestational age and sex 24 ), preeclampsia, pregnancyinduced hypertension, morbidity, and mortality of the neonates.
| Statistical analyses
To detect a clinically relevant difference of 15% in live birth rate, given a reference of 50%, 9,25 a power of 80% with a 2-sided Fisher's exact test at a significance level of 0.05, 170 patients were required in each group. Allowing for a 10% loss to follow up, a total of 400 patients were the final target for recruitment.
The main analysis was based on the intention-to-treat popula- and for important secondary variables, risk differences and risk ratios with 95% CI and exact 95% CI for the estimated proportions were calculated. All significance tests were two-sided and conducted at the 5% significance level.
| Ethical approval
The study was approved by the Regional Ethical Review Board at the researchweb.org, project number 322) before recruitment started.
An additional registration was performed on 6 July 2016 at www.
clinicaltrials.gov after recruitment was completed (NCT 02823743).
The first patient was randomized on 6 March 2008.
| RE SULTS

| Patients
During within the couples was present in 52%. The medical and obstetric history, demography, and history of previous diseases are presented in Table 1 . Thyroid disease and anxiety disorders were reported by 58 women (29%). Allergy, mostly to pollen and without regular medication, was reported by 136 women (34%). All demographic variables were evenly distributed between randomization groups. Women were randomized at a mean gestational age of 45.5
(SD 4.6) days. Conception was spontaneous in 356 (89.0%), through IVF in 31 (7.8%) and as a result of ovarian stimulation in 13 (3.2%)
women.
Follow up of pregnancies was completed in July 2016 and included 400 patients. Approximately 90% of visits at randomization and during follow up were accounted for by the PI. The remaining visits were carried out at local hospitals due to the long distance from the study site and reported to the PI.
| Outcomes
The primary outcome was live birth, according to the intention-totreat analysis, and did not differ between the randomization groups.
Live birth rates were 83.0% and 85.5%, for patients having received ASA and placebo, respectively ( Table 2 ). The difference was −2.5% (95% CI −10.1% to 5.1%). Ninety-eight percent of deliveries were singletons, the remaining being twins, four in the ASA, and four in the placebo group. Six of the eight multiple pregnancies were spontaneous, one was through IVF due to endometriosis, and one after ovarian stimulation due to polycystic ovary syndrome.
Pregnancy loss occurred at similar rates in the two randomization groups ( Table 2 ). In the ASA group, four of five late miscarriages (in gestational weeks 17-21) had a verified uterine infection. One pregnancy was terminated in gestational week 19 due to hydrocephalus. The placebo group included two late pregnancy losses discovered at routine ultrasound at gestational week 19 and one intrauterine death postterm.
Obstetric complications occurred at similar rates in the two randomization groups (Table 2) . Vaginal bleeding occurred in 17.2%.
Three women, two in the ASA and one in the placebo group, had severe bleeding that required admittance to hospital and surveillance but without any intervention.
| Compliance
All participants reported absolute adherence to treatment. Platelet aggregation was analyzed at baseline in 176 and 177 in the ASA and placebo groups, respectively. Women treated with ASA had markedly decreased platelet aggregation compared with women in the placebo group ( Figure 2 ). The reduced numbers in gestational week 13 for the two groups are explained by miscarriage in the first trimester.
| Adverse events
Spontaneously reported side effects for treatment were minor bleedings from nose and gums, small bruises, and long duration of bleeding after blood sampling. A few patients also reported nausea and gastritis. Total side effects were reported in 16.8% and 10.4% in the ASA and the placebo groups, respectively. Events associated with bleeding were reported in 16.2% and 9.2%, respectively.
| D ISCUSS I ON
This large trial, in couples with at least three consecutive miscarriages in the first trimester and of unknown etiology, has demonstrated that 75 mg ASA compared with placebo does not prevent 
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Randomized (n = 400) Enrollment fetal loss. The live birth rate was high. Three other studies using the same definition of RPL report the same absence of benefit of ASA. 15, 23, 26 One small RCT compared the effect of ASA with placebo, although with a lower dose of ASA (50 mg). 23 A similarly high live birth rate (81%) was demonstrated in both groups. In another RCT, the effect of 100 mg ASA was compared with 40 mg enoxaparin, resulting in live birth rates of 84% and 82%, respectively. 15 In a large observational study (n = 805), comparing the effect of 75 mg ASA to no treatment, the live birth rates were 68% and 64%, respectively. 26 Hence, none of these studies involving ASA in the treatment of RPL with three or more miscarriages has demonstrated any benefit in terms of reduced pregnancy loss or increased live birth rate.
Neither of two RCTs, that used the definition of at least two miscarriages, has demonstrated any positive effect of ASA. 27, 28 It is problematic that trials on recurrent miscarriages use different definitions and criteria; at least two or three consecutive miscarriages. According to several guidelines, RPL has traditionally been defined as three or more consecutive miscarriages occurring before 20 weeks of amenorrhea. 2, 3, 29, 30 However, the European Society for
Human Reproduction & Embryology recently published an updated guideline, using the definition of at least two miscarriages before gestational week 24, albeit without consensus in the guideline group. 31 The risk of new miscarriage is estimated to be 20%-26% after two previous miscarriages 4, 25 and 45%-50% after three previous miscarriages, 3, 4, 25 suggesting that the risk of a new pregnancy loss is higher after three than after two miscarriages. Accordingly, we have chosen the definition including three or more miscarriages, which also is in line with the Swedish guideline.
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There is also a difference in time for start of treatment. Among the studies evaluating the effect of ASA, two started treatment within 5 weeks of amenorrhea 23, 26 and three started when a viable pregnancy was demonstrated. 15, 27, 28 In our trial, treatment was started after an early confirmation of viable pregnancy and we cannot answer the question if ASA before conception could prevent RPL. No study has reported the effect of ASA initiated before ovulation or conception.
The couples in our trial had experienced 3-7 consecutive miscarriages and about 15% of the women had a new pregnancy loss with or without active treatment. This miscarriage rate is similar to the results of other RCTs, 15, 23 but considerably lower than from observational studies. 1, 5, 9, 26 The high live birth rate in the present trial, as well as in others, may indicate that the prognosis for this study group is very good. An explanation for the high success rate in our trial may be the rather extensive control program that was applied to both groups. Another study with intense surveillance during pregnancy has also reported high success rates. 28 Already in 1954, Javert wrote about the need for psychotherapy for patients with RPL. 33 Later, many other authors noted the importance of good support during pregnancy. 1, 9, 34 The risk for emotional distress, anxiety, depression, and social withdrawal in the miscarriage patient has also been pointed out. 35 It seems important that treatment for couples with RPL includes emotional support and planned controls by the same doctor/personnel.
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There is also a difference among trials regarding inclusion of late miscarriages in the definition of RPL. The majority of trials use gestational length up to 22 weeks for inclusion, while others define the limit by the first trimester. 5, 15, 23 We believe that the latter definition is the most valid in trials, as pregnancy losses in the second trimester are often characterized by other etiologies like uterine infection and cervical incompetence. 19 Four of the seven late miscarriages in the current trial had a verified intrauterine infection.
The results also strengthen the previous perception that improved endometrial and uterine circulation in the early pregnancy by ASA treatment does not seem to be a key factor for successful outcome in patients with RPL with unknown etiology. Some studies indicate that, in normal pregnancies, a physiological hypoxia due to limited blood flow in the intervillous space during the first trimester is necessary. 37, 38 In early pregnancy complications, the placenta seems to be hypervascularized in color flow mapping by Doppler ultrasonography, 39 which exposes syncytiotrophoblasts to excess maternal blood supply and hence high oxygen levels, which have been associated with early pregnancy loss and preeclampsia. 40, 41 The strengths of this trial are the large sample size, the complete follow up, the total adherence to the study protocol, also supported by the analyses of platelet aggregation, and the use of the definition of at least three consecutive miscarriages in the first trimester. We believe that the complete patient compliance is owing to the PI's dedication to the participants of the trial. It can also be argued that compliance cannot be guaranteed, because drug parcels were not returned. One limitation is that adverse effects were reported in response to an open question and not according to a prespecified report form at the different visits during pregnancy. However, we believe that the strict control program handled by the PI, managed to capture all potential complaints from patients.
| CON CLUS ION
Treatment with 75 mg ASA initiated after the detection of a viable pregnancy is not effective in reducing the risk of RPL in couples with at least three previous miscarriages in the first trimester and no thrombophilia. The high live birth rate above 80%
implies that this population has a very good prognosis for a subsequent live birth.
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